RBC Capital analyst Randall Stanicky maintained a Hold rating on Amneal Pharmaceuticals (NYSE:AMRX) Inc on Thursday, setting a price target of $4, which is approximately 9.30% below the present share price of $4.41.
Stanicky expects Amneal Pharmaceuticals Inc to post earnings per share (EPS) of $0.78 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Amneal Pharmaceuticals, with an average price target of $4.25.
The analysts price targets range from a high of $5 to a low of $4.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $498.53 million and a net profit of $66.91 million. The company's market cap is $1.32 billion.
According to TipRanks.com, RBC Capital analyst Randall Stanicky is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.9% and a 33.73% success rate.
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.